Inflammatory response mediates cross-talk with immune function and reveals clinical features in acute myeloid leukemia. Issue 5 (27th May 2022)

• Record Type: Journal Article
• Authors: Zhong, Fang-Min; Yao, Fang-Yi; Liu, Jing; Zhang, Hai-Bin; Li, Mei-Yong; Jiang, Jun-Yao; Xu, Yan-Mei; Yang, Wei-Ming; Li, Shu-Qi; Zhang, Jing; Cheng, Ying; Xu, Shuai; Huang, Bo; Wang, Xiao-Zhong
• Is Part Of: Bioscience reports. Volume 42:Issue 5(2022)
• Publication Date: 2022-05-27
• Subjects: acute myeloid leukemia -- immune function -- inflammatory response -- prognosis -- tumor microenvironment; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20220647
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Accumulated genetic mutations are an important cause for the development of acute myeloid leukemia (AML), but abnormal changes in the inflammatory microenvironment also have regulatory effects on AML. Exploring the relationship between inflammatory response and pathological features of AML has implications for clinical diagnosis, treatment and prognosis evaluation. We analyzed the expression variation landscape of inflammatory response-related genes (IRRGs) and calculated an inflammatory response score for each sample using the gene set variation analysis (GSVA) algorithm. The differences in clinical- and immune-related characteristics between high- and low-inflammatory response groups were further analyzed. We found that most IRRGs were highly expressed in AML samples, and patients with high inflammatory response had poor prognosis and were accompanied with highly activated chemokine-, cytokine- and adhesion molecule-related signaling pathways, higher infiltration ratios of monocytes, neutrophils and M2 macrophages, high activity of type I/II interferon (IFN) response, and higher expression of immune checkpoints. We also used the Genomics of Drug Sensitivity in Cancer (GDSC) database to predict the sensitivity of AML samples with different inflammatory responses to common drugs, and found that AML samples with low inflammatory response were more sensitive to cytarabine, doxorubicin and midostaurin. SubMap algorithm also demonstrated that high-inflammatory response patients are more suitable for anti-PD-1 immunotherapy. Finally, we constructed a prognostic risk score model to predict the overall survival (OS) of AML patients. Patients with higher risk score had significantly shorter OS, which was confirmed in two validation cohorts. The analysis of inflammatory response patterns can help us better understand the differences in tumor microenvironment (TME) of AML patients, and guide clinical medication and prognosis prediction.